氘代丁苯那嗪作为亨廷顿舞蹈病和迟发性运动障碍相关舞蹈症治疗选择的临床效用
Clinical Utility of Deutetrabenazine as a Treatment Option for Chorea Associated with Huntington's Disease and Tardive Dyskinesia.
作者信息
Frank Samuel, Alakkas Aljoharah
机构信息
Department of Neurology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, USA.
Department of Neurology, National Neuroscience Institute, King Fahad Medical City, Riyadh, K.S.A.
出版信息
Ther Clin Risk Manag. 2023 Dec 1;19:1019-1024. doi: 10.2147/TCRM.S279332. eCollection 2023.
Deutetrabenazine (DTBZ) is used for the treatment of tardive dyskinesia (TD) and chorea in Huntington's Disease (HD). Four pivotal clinical trials showed the efficacy of DTBZ in these conditions. Long term follow-up studies confirmed evidence of overall safety and continued efficacy of this drug. Indirect comparisons revealed relative superiority of DTBZ over TBZ in terms of safety, but direct comparisons of safety and efficacy between the VMAT2 and dopamine blocking agents is lacking. Deutetrabenazine is safe and effective in the treatment of TD and chorea in HD in doses up to 72 mg daily and for up to three years in duration.
氘代丁苯那嗪（DTBZ）用于治疗亨廷顿舞蹈症（HD）中的迟发性运动障碍（TD）和舞蹈症。四项关键临床试验表明DTBZ在这些病症中具有疗效。长期随访研究证实了该药物总体安全性及持续疗效的证据。间接比较显示DTBZ在安全性方面相对优于丁苯那嗪（TBZ），但缺乏VMAT2抑制剂与多巴胺阻滞剂之间安全性和疗效的直接比较。氘代丁苯那嗪在治疗HD中的TD和舞蹈症时，每日剂量高达72mg、疗程长达三年是安全有效的。
Zotero 插件